Page 2 - Biliary Tract News Today

Researchers report endoscopic features and propose diagnostic criteria for post–COVID-19 cholangiopathy — one of the most serious long-term gastrointestinal consequences of COVID-19.

Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.

In a debate held recently on the use of neoadjuvant therapy for high-risk intrahepatic cholangiocarcinoma, both sides agreed that more research is needed.

Stay connected with Business News This Week for business news, news this week, news headlines, business news, health, education, startups

Antibiotic use doesn’t appear to disrupt the effectiveness of the immune checkpoint inhibitor durvalumab in advanced biliary tract cancer, according to a new analysis of TOPAZ-1 clinical trial data.

Investegate announcements from AstraZeneca PLC, Imfinzi recommended for approval in the EU for BTC

AstraZeneca's Imfinzi recommended for approval in EU for BTC

AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The Committee for Medicinal Products ...

HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial